Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT02638948

Public ClinicalTrials.gov record NCT02638948. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety/Pharmacokinetics of BMS-986142 in Subjects With Moderate to Severe Rheumatoid Arthritis With an Inadequate Response to Methotrexate With or Without TNF Inhibitors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine whether the study drug, BMS-986142, is safe and effective in treating moderate to severe rheumatoid arthritis in subjects with an inadequate response to methotrexate or methotrexate and up to 2 tumour necrosis factor (TNF) Inhibitors. Patients who qualify will be randomized to either one of 3 doses of BMS-986142 or placebo in 1:1:1 randomization for 12 weeks. Disease activity and safety will be assessed over the course of the study.

Study identification

NCT ID
NCT02638948
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
508 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 120 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 15, 2016
Primary completion
May 2, 2018
Completion
May 2, 2018
Last update posted
May 27, 2019

2016 – 2018

United States locations

U.S. sites
26
U.S. states
12
U.S. cities
23
Facility City State ZIP Site status
Rheumatology Associates Of North Alabama, P.C. Huntsville Alabama 35801
St. Joseph Heritage Medical Group Fullerton California 92835
C.V Mehta M.D Medical Corp Hemet California 92543
HCP Clinical Research, LLC Huntington Beach California 92646
Leon Medical Research Miami Florida 33015
San Marcus Research Clinic, Inc. Miami Florida 33015
Coral Research Clinic Corp Miami Florida 33175
Precision Research Organization Miami Lakes Florida 33016
The Arthritis Center Palm Harbor Florida 34684
Vizae Clinical Trials Management Pembroke Pines Florida 33026
Integral Rheumatology & Immunology Specialists Plantation Florida 33324
North Georgia Rheumatology Group Lawrenceville Georgia 30046
Arthritis And Diabetes Clinic Monroe Louisiana 71203
Clinical Pharmacology Study Group Worcester Massachusetts 01605
Aa Mrc Llc Grand Blanc Michigan 48439
Albuquerque Center For Rheumatology Albuquerque New Mexico 87102
Albuquerque Clinical Trials Albuquerque New Mexico 87102
Paramount Medical Research & Consulting, Llc Middleburg Heights Ohio 44130
East Penn Rheumatology Bethlehem Pennsylvania 18015
Altoona Center For Clinical Research Duncansville Pennsylvania 16635-8406
Advanced Rheumatology & Arthritis Research Center, P.C Wexford Pennsylvania 15090
Local Institution Wyomissing Pennsylvania 19610
West Tennessee Research Institute Jackson Tennessee 38305
Pharma Tex Research Amarillo Texas 79106
Tekton Research Inc Austin Texas 78745
Southwest Rheumatology Research LLC Mesquite Texas 75150

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 78 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02638948, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 27, 2019 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02638948 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →